Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.

ABSTRACT:

Background and objective

Tolvaptan, an oral vasopressin V2 receptor antagonist, has been widely used for the treatment of patients with cirrhosis and ascites. However, its efficacy in patients with renal dysfunction remains unknown. The objective of this study was to investigate the efficacy and safety of tolvaptan in patients with decompensated cirrhosis and severe chronic kidney disease (s-CKD).

Methods

We studied 43 patients with liver cirrhosis who received tolvaptan (7.5 mg/day) for refractory ascites. s-CKD was defined as an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m². Response to tolvaptan was defined as weight loss ≥ 1.5 kg in 7 days of treatment.

Results

Eighteen patients (42%) had s-CKD (s-CKD group), while the other 25 patient

SUBMITTER: Arase Y 

PROVIDER: S-EPMC6510826 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature